Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
budesonide + ipratropium bromide
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Budesonide + ipratropium bromide is a combination medication used for respiratory conditions. Budesonide is a corticosteroid with anti-inflammatory properties that prevents inflammation in the lungs, while ipratropium bromide is an anticholinergic bronchodilator that relaxes airway smooth muscles. This combination provides complementary effects for treating conditions like COPD exacerbations, bronchopneumonia, and preventing ARDS in high-risk patients.
02
Targets
CHRM3 (M3)CHRM2 (M2)GR (Glucocorticoid receptor)M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on budesonide + ipratropium bromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on budesonide + ipratropium bromide.